Sep 30, 2021 03:53PM
Sep 30, 2021 03:52PM
Sep 30, 2021 06:52AM
Sep 30, 2021 06:46AM
Sep 30, 2021 06:45AM
Jul 28, 2021 06:59AM
May 19, 2021 08:03AM Acceleron Pharma (XLRN) Highlights Interim Results from Open-label Extension of PULSAR Phase 2 Trial of Sotatercept in Patients with PAH
May 19, 2021 08:03AM
May 19, 2021 08:00AM
May 19, 2021 08:00AM
May 11, 2021 07:00AM
Apr 28, 2021 11:17AM
Apr 5, 2021 07:10AM
Apr 5, 2021 07:00AM Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the American Thoracic Society (ATS) 2021 International Conference
Apr 1, 2021 07:02AM
Apr 1, 2021 07:00AM
Feb 25, 2021 04:01PM
Dec 14, 2020 07:02AM
Dec 14, 2020 07:00AM
Dec 1, 2020 07:06AM
Dec 1, 2020 07:00AM Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis
Nov 13, 2020 10:05AM
Nov 13, 2020 10:03AM
Nov 13, 2020 10:01AM
Nov 13, 2020 10:00AM
Nov 9, 2020 07:26AM
Nov 9, 2020 07:00AM
Sep 17, 2020 04:01PM Acceleron to Host Webcast Outlining the Design of Its Registrational Phase 3 STELLAR Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) on October 2, 2020
Aug 6, 2020 04:01PM
Jun 24, 2020 03:15PM
Jun 24, 2020 03:15PM
Jun 22, 2020 07:00AM
May 19, 2020 07:00AM
May 13, 2020 04:01PM
May 11, 2020 04:25PM Acceleron Pharma (XLRN) Misses Q1 EPS by 9c
May 11, 2020 04:05PM
May 4, 2020 07:04AM
May 4, 2020 07:00AM
Apr 8, 2020 07:08AM
Apr 8, 2020 07:05AM
Apr 3, 2020 05:08PM
Mar 26, 2020 07:01AM Bristol-Myers Squibb (BMY) and Acceleron (XLRN) Announces NEJM Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl in Adult Patients With Beta Thalassemia
Mar 26, 2020 06:59AM
Feb 27, 2020 04:17PM
Feb 27, 2020 04:05PM
Jan 28, 2020 09:23AM
Jan 28, 2020 07:29AM
Jan 27, 2020 05:58PM
Jan 9, 2020 07:00AM Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce NEJM Publishes Results of Pivotal Phase 3 Reblozyl MEDALIST Trial
Jan 9, 2020 06:59AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All